Cornerstone Advisory’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-8,298
| Closed | -$233K | – | 288 |
|
|
2026
Q1 | $233K | Sell |
8,298
-475
| -5% | -$12.6K | 0.02% | 235 |
|
|
2025
Q4 | $218K | Sell |
8,773
-212
| -2% | -$5.35K | 0.02% | 235 |
|
|
2025
Q3 | $229K | Sell |
8,985
-4,172
| -32% | -$103K | 0.02% | 223 |
|
|
2025
Q2 | $319K | Buy |
13,157
+2,841
| +28% | +$66.3K | 0.03% | 177 |
|
|
2025
Q1 | $236K | Sell |
10,316
-2,724
| -21% | -$71.3K | 0.03% | 203 |
|
|
2024
Q4 | $333K | Sell |
13,040
-3,749
| -22% | -$102K | 0.04% | 178 |
|
|
2024
Q3 | $486K | Sell |
16,789
-413
| -2% | -$12K | 0.06% | 136 |
|
|
2024
Q2 | $481K | Sell |
17,202
-7,541
| -30% | -$208K | 0.07% | 128 |
|
|
2024
Q1 | $687K | Sell |
24,743
-4,389
| -15% | -$122K | 0.1% | 116 |
|
|
2023
Q4 | $839K | Buy |
29,132
+45
| +0.2% | +$1.36K | 0.13% | 97 |
|
|
2023
Q3 | $965K | Sell |
29,087
-2,814
| -9% | -$99.5K | 0.17% | 82 |
|
|
2023
Q2 | $1.17M | Sell |
31,901
-4,011
| -11% | -$156K | 0.21% | 69 |
|
|
2023
Q1 | $1.47M | Sell |
35,912
-872
| -2% | -$37.7K | 0.26% | 58 |
|
|
2022
Q4 | $1.88M | Buy |
36,784
+2,172
| +6% | +$104K | 0.37% | 46 |
|
|
2022
Q3 | $1.51M | Buy |
34,612
+1,846
| +6% | +$89.7K | 0.34% | 51 |
|
|
2022
Q2 | $1.72M | Sell |
32,766
-21,738
| -40% | -$1.11M | 0.39% | 46 |
|
|
2022
Q1 | $2.82M | Sell |
54,504
-125
| -0.2% | -$6.49K | 0.43% | 42 |
|
|
2021
Q4 | $3.23M | Sell |
54,629
-1,683
| -3% | -$83.4K | 0.46% | 39 |
|
|
2021
Q3 | $2.42M | Buy |
56,312
+2,044
| +4% | +$90.5K | 0.4% | 45 |
|
|
2021
Q2 | $2.13M | Buy |
54,268
+9,622
| +22% | +$374K | 0.36% | 52 |
|
|
2021
Q1 | $1.62M | Buy |
44,646
+4,386
| +11% | +$156K | 0.31% | 62 |
|
|
2020
Q4 | $1.48M | Buy |
40,260
+3,333
| +9% | +$122K | 0.3% | 61 |
|
|
2020
Q3 | $1.29M | Buy |
36,927
+21,403
| +138% | +$750K | 0.3% | 65 |
|
|
2020
Q2 | $482K | Sell |
15,524
-57
| -0.4% | -$1.94K | 0.13% | 116 |
|
|
2020
Q1 | $483K | Sell |
15,581
-4,431
| -22% | -$151K | 0.15% | 93 |
|
|
2019
Q4 | $744K | Buy |
20,012
+4,564
| +30% | +$163K | 0.15% | 89 |
|
|
2019
Q3 | $527K | Buy |
15,448
+1
| +0% | +$36 | 0.11% | 103 |
|
|
2019
Q2 | $635K | Sell |
15,447
-88
| -0.6% | -$3.49K | 0.14% | 93 |
|
|
2019
Q1 | $626K | Buy |
15,535
+756
| +5% | +$30.3K | 0.14% | 94 |
|
|
2018
Q4 | $612K | Buy |
14,779
+1,657
| +13% | +$68.8K | 0.16% | 87 |
|
|
2018
Q3 | $549K | Sell |
13,122
-1,459
| -10% | -$56.2K | 0.16% | 89 |
|
|
2018
Q2 | $502K | Hold |
14,581
| – | – | 0.17% | 90 |
|
|
2018
Q1 | $491K | Sell |
14,581
-1,802
| -11% | -$61.9K | 0.18% | 90 |
|
|
2017
Q4 | $563K | Buy |
16,383
+1,458
| +10% | +$49.7K | 0.19% | 90 |
|
|
2017
Q3 | $506K | Sell |
14,925
-1,089
| -7% | -$35K | 0.17% | 93 |
|
|
2017
Q2 | $510K | Buy |
16,014
+748
| +5% | +$23.6K | 0.17% | 90 |
|
|
2017
Q1 | $495K | Buy |
15,266
+382
| +3% | +$12K | 0.25% | 60 |
|
|
2016
Q4 | $459K | Sell |
14,884
-474
| -3% | -$14.5K | 0.34% | 46 |
|
|
2016
Q3 | $494K | Buy |
15,358
+474
| +3% | +$15.8K | 0.41% | 39 |
|
|
2016
Q2 | $497K | Hold |
14,884
| – | – | 0.42% | 38 |
|
|
2016
Q1 | $419K | Sell |
14,884
-51
| -0.3% | -$1.46K | 0.36% | 43 |
|
|
2015
Q4 | $457K | Buy |
+14,935
| New | +$470K | 0.39% | 41 |
|
Other funds holding PFE
Cornerstone Advisory's PFE Position: Q2 2026 in Review
Cornerstone Advisory sold out of Pfizer (PFE) in Q2 2026, closing a stake of 8,298 shares — an estimated $233K sold.
Cornerstone Advisory first reported a position in PFE in Q4 2015 and held it in 42 quarters. The position peaked at $3.23M in Q4 2021. 2,820 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Cornerstone Advisory reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
- Cornerstone Advisory sold 8,298 Pfizer shares in Q2 2026, an estimated $233K.
- Cornerstone Advisory first reported a position in Pfizer in Q4 2015 and held it in 42 quarters.
- Cornerstone Advisory's Pfizer position peaked at $3.23M in Q4 2021.
- 2,820 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Cornerstone Advisory's 13F filing for Q2 2026, filed 29 Jul 2026.